Press release
Full-process Services of Eukaryotic Microbial 18S Sequencing at Creative Biogene
Microbialtec Lab is one of the main business units in Creative Biogene, which is dedicated to offering full-process services of eukaryotic microbial 18S sequencing from DNA extraction to PCR amplification, purification, sequencing, and analysis of eukaryotic microbes.18S ribosomal RNA is a structural RNA for the small element of eukaryotic cytoplasmic ribosomes. Owing to its high specificity and sequence conservation, the 18S rRNA gene has been regarded as the most commonly used marker for exploring the community structure of eukaryotic protists in aquatic and terrestrial environments. For example, the 18S rDNA gene can be utilized for the identification and molecular systematics of eukaryotic microorganisms such as microalgae and protozoa.
For over a decade, Creative Biogene has been focused on microbiological research and is now capable of providing 18S rRNA gene sequencing services to help researchers identify, classify, and quantify microbes within complex biological mixtures. Clients can choose different service packages featured with wide applicability, cost-efficiency, and high speed according to their project needs.
To simplify clients' 18S rRNA identification process, the company releases 3 service packages covering sequence amplification of 18S rRNA, sequencing of PCR products, cloning of related genes, and sequencing alignment analysis within a 1-2 weeks turnaround time. In addition, the expert team can also construct gene libraries of eukaryotic microbial 18S rDNA and develop RFLP makers within 5-6 weeks to provide a full analysis of eukaryotic microbial community diversity.
"Our 16S/18S/ITS amplicon sequencing is supportive of identifying and investigating the microbial community. With over 10 years of experience, we can meet your project requirements and budgets in the exploration of microbial biodiversity and optimize your biological and therapeutic research. We have advanced sequencing platforms and a diverse range of one-stop eukaryotic microbial 18S sequencing services to enable comprehensive bioinformatic analysis and in-depth microbiological studies," the marketing manager at Creative Biogene said.
Creative Biogene
New York, USA
Marcia Brady
+1 631 386 8241
About Creative Biogene
Creative Biogene aims to provide the latest strategies of high-level microbiological research services to pharmaceutical researchers and industrial partners all over the world. With years of experience, the company is capable of offering customers an overall microbiological research program, including sample collection, preservation methods, preliminary experiments and impact evaluation, experiments and data analysis, etc. Creative Biogene is dedicated to assisting researchers in exploring the hidden mysteries between microbes and health, production, and the environment to better use microbial resources.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Full-process Services of Eukaryotic Microbial 18S Sequencing at Creative Biogene here
News-ID: 2695034 • Views: …
More Releases from Creative Biogene
Full-Scale Mitochondrial Bioenergetics Services at Creative Biogene
As one of the leading bio-companies engaged in mitochondrial research, Creative Biogene, together with its large team of experts, creates a powerful mitochondrial research service platform. To satisfy the research needs of global customers on mitochondrial bioenergies, Creative Biogene provides partners with a comprehensive range of mitochondrial bioenergetics detection and analysis services based on years of experience and high-end instruments.
Mitochondria are the primary source of ATP for most cells…

Genetically Steady and Cost-effective Gene Knockout Stable Cell Lines Products a …
Creative Biogene creatively develops a series of genetically steady and cost-effective gene knockout stable cell lines products for domestic and overseas clients.
New York, United States - December 02, 2021—With years of experience in the gene-engineering field, Creative Biogene has built a team of experts to perform genome editing with CRISPR/Cas9 technology, from designing gRNA to transfection and single clone generation. After rigorous and copious experiments and tests, Creative Biogene can…
Creative Biogene Offers One-Stop Customized CRISPR Based Microbe Genome Editing …
Creative Biogene Offers One-Stop Customized CRISPR Based Microbe Genome Editing Service for global clients.
New York, United States - August 18, 2021—Creative Biogene has been dedicated itself to undertaking the cause of bioscience for decades and enjoys rich experiences and expertise in CRISPR gene-editing areas. Through years of efforts and competitive advantages, its CRISPR-based microbe genome editing service is rather renowned at home and abroad.
CRISPR/Cas9 platform, which is a mature and…
CRISPR/Cas9 Platform: One Stop Custom Knock-in Cell Line Generation Service
CRISPR/Cas9 Platform, the major division of Creative Biogene, is committed to applying CRISPR/Cas9 technology in different fields with comprehensive gene editing services and products, including gene knockout, gene knockin and point mutation. One of the new launched service is the one stop custom knock-in cell line generation service which can be applied in the field of gene editing.
The CRISPR/Cas9 platform provides customized knock-in cell line generation services, including point mutation…
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand.
Browse 156 Market Data Tables and 112 Figures spread through 175…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited.
Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring…
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year.
Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved…
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018!
Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led…
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion.
One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and…